Survac Overview

  • Founded
  • 2003
Founded
  • Status
  • Acquired/​Merged
  • Latest Deal Type
  • M&A
  • Latest Deal Amount
  • $13.1M
Latest Deal Amount

Survac General Information

Description

Developer of peptides based technology for therapeutic cancer vaccines. The company provides technology to identify and modify peptides that are useful for therapeutic cancer vaccines.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Acquirer
Primary Office
  • Esthersvej 27
  • 2900 Hellerup
  • Denmark
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Survac Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Merger/Acquisition 18-Nov-2005 $13.1M 000.00 Completed Startup
2. Early Stage VC Completed Startup
1. Early Stage VC 01-Jan-2003 Completed Startup
To view Survac’s complete valuation and funding history, request access »

Survac Executive Team (2)

Name Title Board Seat Contact Info
Mads Andersen Ph.D Chief Executive Officer & Co-Founder
Per Straten Ph.D Co-Founder
To view Survac’s complete executive team members history, request access »

Survac Former Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Seed Capital (Denmark) Venture Capital Minority 000 0000 000000 0
Technical University of Denmark (Endowment) Limited Partner Minority 000 0000 000000 0
To view Survac’s complete investors history, request access »